According to the complaint, defendants made false and/or misleading statements and/or failed to disclose that:
- defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates;
- defendants materially overstated the quality of Telix’s supply chain and partners; and
- as a result, defendants’ statements about Telix’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
